GI side effects may worsen, and clearance is unknown
doi: 10.1016/j.clnu.2020.10.034 143
This Isn't Really About BPC-157: The Bigger Picture of the FDA's Meeting on Peptides By Oliver Catlin , President, Banned Substances Control Group (BSCG) If you've been following the FDA's upcoming discussion on unapproved peptides, you've probably seen the conversation revolve around familiar names like BPC-157, TB-500, KPV, and MOTS-c
Alzheimers disease drug-development pipeline: few candidates, frequent failures
Nowowiejska L, Marek-Jzefowicz L, Szewczyk-Golec K, Woniak A, Basaygo M, Zegarska B, et al
Diagnosis Demographic data were obtained for each subject from medical records at the time of the enrollment and included current age, sex and family history of hypertension and stroke